All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Scorr-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Cabaletta Bio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

BIO International Convention

Participation Not Confirmed

Update your events

Cabaletta Bio Receives FDA Fast Track Designation for DSG3-CAART for the Treatment of Mucosal Pemphigus Vulgaris

Contact the Supplier

Lead Product(s): Desmoglein 3 Chimeric AutoAntibody Receptor T cells

Therapeutic Area: Immunology

Highest Development Status: IND Enabling Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 06, 2020

Details:

U.S. FDA has granted Fast Track Designation for DSG3-CAART, the Cabaletta’s lead product for treatment of mucosal pemphigus vulgaris, for improving healing of mucosal blisters in patients with mPV.